## Radim BeÄvÃ;Å™

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7191781/publications.pdf

Version: 2024-02-01

623188 500791 14 10,591 36 28 citations g-index h-index papers 37 37 37 14830 docs citations times ranked citing authors all docs

#	Article	IF	Citations
1	Plasma Hsp90 levels in patients with systemic sclerosis and relation to lung and skin involvement: a cross-sectional and longitudinal study. Scientific Reports, 2021, 11, 1.	1.6	9,439
2	Mapping and predicting mortality from systemic sclerosis. Annals of the Rheumatic Diseases, 2017, 76, 1897-1905.	0.5	410
3	Nailfold capillaroscopy in systemic sclerosis: Data from the EULAR scleroderma trials and research (EUSTAR) database. Microvascular Research, 2013, 89, 122-128.	1.1	101
4	European multicentre study to define disease activity criteria for systemic sclerosis. I. Clinical and epidemiological features of 290 patients from 19 centres. Annals of the Rheumatic Diseases, 2001, 60, 585-591.	0.5	83
5	Heat shock protein 90 (Hsp90) inhibition targets canonical TGF-β signalling to prevent fibrosis. Annals of the Rheumatic Diseases, 2014, 73, 1215-1222.	0.5	78
6	Phenotypes Determined by Cluster Analysis and Their Survival in the Prospective European Scleroderma Trials and Research Cohort of Patients With Systemic Sclerosis. Arthritis and Rheumatology, 2019, 71, 1553-1570.	2.9	75
7	Riociguat in patients with early diffuse cutaneous systemic sclerosis (RISE-SSc): randomised, double-blind, placebo-controlled multicentre trial. Annals of the Rheumatic Diseases, 2020, 79, 618-625.	0.5	71
8	Cytokines and adhesion molecules in renal vasculitis and lupus nephritis. Nephrology Dialysis Transplantation, 1998, 13, 1662-1667.	0.4	68
9	S100A4 amplifies TGF-Î <sup>2</sup> -induced fibroblast activation in systemic sclerosis. Annals of the Rheumatic Diseases, 2015, 74, 1748-1755.	0.5	52
10	Tribbles homologue 3 stimulates canonical TGF- $\hat{l}^2$ signalling to regulate fibroblast activation and tissue fibrosis. Annals of the Rheumatic Diseases, 2016, 75, 609-616.	0.5	38
11	Adiponectin relation to skin changes and dyslipidemia in systemic sclerosis. Cytokine, 2012, 58, 165-168.	1.4	29
12	Glycosaminoglycan polysulfuric acid (GAGPS) in osteoarthritis of the knee. Osteoarthritis and Cartilage, 1995, 3, 15-23.	0.6	22
13	Interleukin-35 is upregulated in systemic sclerosis and its serum levels are associated with early disease. Rheumatology, 2015, 54, kev260.	0.9	17
14	Clinical Correlations of Potential Activity Markers in Systemic Sclerosis. Annals of the New York Academy of Sciences, 2005, 1051, 404-412.	1.8	15
15	Verrucous form of chilblain lupus erythematosus. Journal of the European Academy of Dermatology and Venereology, 2001, 15, 448-451.	1.3	14
16	Prevalence of Antinucleosome Antibodies by Enzyme-Linked Immunosorbent Assays in Patients with Systemic Lupus Erythematosus and Other Autoimmune Systemic Diseases. Annals of the New York Academy of Sciences, 2007, 1109, 275-286.	1.8	14
17	Pulmonary arterial hypertension associated with systemic sclerosis in the Czech Republic. Clinical Rheumatology, 2012, 31, 557-561.	1.0	14
18	A comparison between nailfold capillaroscopy patterns in adulthood in juvenile and adult-onset systemic sclerosis: A EUSTAR exploratory study. Microvascular Research, 2015, 102, 19-24.	1.1	13

#	Article	IF	CITATIONS
19	Polymorphism of the extrapituitary prolactin promoter and systemic sclerosis. Rheumatology International, 2010, 30, 1691-1693.	1.5	10
20	Markers of collagen metabolism in sera of patients with various rheumatic diseases. Clinica Chimica Acta, 1989, 183, 243-252.	0.5	7
21	Von Willebrand factor antigen and adhesive molecules in Wegener's granulomatosis and microscopic polyangiitis. Clinical Rheumatology, 1997, 16, 324-325.	1.0	5
22	Inhibition of Hsp90 Counteracts the Established Experimental Dermal Fibrosis Induced by Bleomycin. Biomedicines, 2021, 9, 650.	1.4	5
23	Anticollagen antibodies in patients with juvenile chronic arthritis. Clinical Rheumatology, 1988, 7, 378-383.	1.0	3
24	Nabumetone Induces Less Gastrointestinal Mucosal Changes Than Diclofenac Retard. Clinical Rheumatology, 1999, 18, 273-278.	1.0	3
25	A3.16â€Serum S100A4 correlates with skin fibrosis, lung involvement and disease activity in systemic sclerosis. Annals of the Rheumatic Diseases, 2014, 73, A48.1-A48.	0.5	1
26	AB0203â€S100A4 Serum Levels Correlate with Disease Activity, Skin Fibrosis and Lung Involvement in Systemic Sclerosis. Annals of the Rheumatic Diseases, 2014, 73, 871.1-871.	0.5	1
27	A3.10 Plasma levels of heat shock protein 90 correlate with disease activity, lung involvement and skin fibrosis in systemic sclerosis. Annals of the Rheumatic Diseases, 2015, 74, A35.1-A35.	0.5	1
28	S100A11 (calgizzarin) is released by circulating mononuclear cells and its elevated plasma levels distinguish systemic lupus erythematosus patients from healthy individuals. Clinical and Experimental Rheumatology, 2019, 37, 338-339.	0.4	1
29	The effect of a 24-week physiotherapy and occupational therapy program in systemic sclerosis: a monocentric controlled study with follow-up. Clinical and Experimental Rheumatology, 0, , .	0.4	1
30	A8.3â€Deficit of S100A4 Prevents Joint Destruction and Systemic Bone Loss in hTNFtg Mouse Model. Annals of the Rheumatic Diseases, 2013, 72, A58.1-A58.	0.5	0
31	AB0632â€Association between Interstitial Pulmonary Involvement and Microvaculature Changes in Systemic Sclerosis. Annals of the Rheumatic Diseases, 2016, 75, 1120.3-1120.	0.5	O
32	08.48â€Increased body fat but decreased lean body mass and bone mineral density in myositis patients are associated with disease duration, inflammatory status, skeletal muscle involvement and physical activity. , 2017, , .		0
33	08.49â€Efficacy of an intensive 24-week physiotherapy programme in scleroderma patients – preliminary data from a single-centre controlled study. , 2017, , .		O
34	08.47â€Decreased body fat, lean body mass and bone mineral density in scleroderma patients are associated with disease activity and physical activity., 2017,,.		0
35	OP0066â€EFFECTIVENESS OF SPECIALIZED HAND/FACE PHYSICAL-OCCUPATIONAL THERAPY IN PATIENTS WITH SYSTEMIC SCLEROSIS – PRELIMINARY RESULTS OF A ONE-YEAR CONTROLLED STUDY. , 2019, , .	1	O
36	The effect of a 24-week physiotherapy and occupational therapy program in systemic sclerosis: a monocentric controlled study with follow-up Clinical and Experimental Rheumatology, 2022, , .	0.4	0